Skip to main content
Retour
Watch Compare

MiNK Therapeutics, Inc.

Qualité des données : 83%
INKT
Nasdaq Manufacturing Chemicals
11,04 €
▼ 0,43 € (-3,75%)
Cap. Boursière: 56,46 M
Prix
11,37 €
Cap. Boursière
56,46 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -5,93 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio1,08
Interest Coverage-114,93

Valorisation

PE (TTM)
-4,52
En dessous de la moyenne du secteur (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1366 pairs)
Métrique Action Médiane du Secteur
P/E -4,5 -1,5
P/B — 1,6
ROE % — -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Objectif de Cours des Analystes

2 analystes
Buy
Actuel
11,04 €
+253.3%
Objectif
39,00 €
35,00 €
39,00 €
43,00 €
Prévisions
P/E Prévisionnel -3,20
BPA Prévisionnel -3,45 €
CA Est. 0,0

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 -3,45 €
-3,58 € – -3,32 €
 0,0 2
FY2026 -3,27 €
-3,50 € – -3,03 €
 0,0 2

Surprises de Résultats

Derniers 4 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q42025 -0,68 € -0,56 € +17,7%
Q32025 -0,86 € -0,65 € +24,0%
Q22025 -0,55 € -1,06 € -93,9%
Q12025 -0,61 € -0,70 € -14,8%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -12,49 M
ROE N/A ROA -143,22%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -5,93 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,08
Interest Coverage -114,93 Asset Turnover N/A
Working Capital 1,10 M Tangible Book Value -13,51 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4,52 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -10,49%
Market Cap 56,46 M Enterprise Value 42,18 M
Per Share
EPS (Diluted TTM) -2,93 Revenue / Share N/A
FCF / Share -1,19 OCF / Share -1,19
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 47,42%
SBC-Adj. FCF -8,42 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -12,49 M -10,78 M -22,46 M -27,99 M -30,21 M
EPS (Diluted) -2,93 -2,86 -0,65 -0,83 —
Gross Profit — — — — —
Operating Income -12,64 M -11,29 M -22,92 M -30,95 M -28,36 M
EBITDA — — — — —
R&D Expenses 5,76 M 6,34 M 15,49 M 23,12 M 13,97 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense -110 000,0 -93 000,0 463 256,0 253 323,0 2,43 M
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 14,24 M 5,72 M 4,55 M 21,47 M 40,24 M
Total Liabilities — — — — —
Shareholders' Equity -14,23 M -19,59 M -18,06 M -401 303,0 23,78 M
Total Debt — — — — —
Cash & Equivalents 13,36 M 4,58 M 3,37 M 19,64 M —
Current Assets 13,85 M 4,99 M 3,60 M 20,40 M 39,63 M
Current Liabilities 13,03 M 6,96 M 11,40 M 12,68 M 16,47 M